Abstracts tagged "Systemic sclerosis and therapy"

Abstract Number: 2693 • ACR/ARHP Annual Meeting 2018
What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study
Brigit Kersten, Nathan den Broeder, Frank van den Hoogen, Els van den Ende and Madelon Vonk, Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Patients with systemic sclerosis who have proximal skin involvement are classified as diffuse cutaneous systemic sclerosis (DcSSc). Patients with progressive skin involvement have worse prognosis.…
Abstract Number: 2885 • ACR/ARHP Annual Meeting 2017
Tadalafil Reduces Skin Fibrosis and Profibrotic Genes Expression in Patients with Systemic Sclerosis
Sakir Ahmed, Mohit Kumar Rai, Durga Prasanna Misra and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Currently, drugs that modify skin fibrosis in Systemic Sclerosis (SSc) have efficacy in certain subgroups of patients only. Phosphodiesterase-5 inhibitors (PDE5i) are known to…
Abstract Number: 824 • ACR/ARHP Annual Meeting 2016
Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Donald P. Tashkin², Ning Li³, Michael Roth⁴, Dinesh Khanna⁵, Anna-Maria Hoffmann-Vold⁶, Philip J. Clements⁴, Daniel E. Furst¹, Robert Elashoff⁷ and Scleroderma Lung Study II Group, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶Oslo University Hospital, Oslo, Norway, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function and dyspnea in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).1 While treatment with…
Abstract Number: 845 • ACR/ARHP Annual Meeting 2016
Current Use of Off-Label Therapies in Systemic Sclerosis-Associated Interstitial Lung Disease
Elise Siegert¹, Dörte Huscher², Ulf Müller-Ladner³, Veronika K. Jaeger⁴, Ulrich A. Walker⁴, Marc Frerix⁵, László Czirják⁶, Francesco Del Galdo⁷, Gabriele Valentini⁸, Marco Matucci-Cerinic⁹, Yannick Allanore¹⁰, Oliver Distler¹¹, Christopher Denton¹², Gabriela Riemekasten¹³ and EUSTAR co-authors, ¹Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁴Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁵Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁶Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ⁷Musculoskeletal Diseases, Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, ⁸Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁹Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ¹⁰Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ¹¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹³Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a connective tissue disease that is often complicated by secondary interstitial lung disease (SSc-ILD). Due to its high morbidity and…
Abstract Number: 3176 • ACR/ARHP Annual Meeting 2016
Meta-Analysis of SSc Clinical Trials with Molecular Gene Expression Data Suggests Potential Combination Therapies
Jaclyn N. Taroni¹, Viktor Martyanov² and Michael L. Whitfield², ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Clinical trials in SSc have tended to be underpowered and not meet clinical endpoints. Genome-wide gene expression measured in some studies can prove challenging…
Abstract Number: 708 • ACR/ARHP Annual Meeting 2013
Intravenous Immunoglobulin May Be An Effective Therapy In Scleroderma Patients With Refractory Active Diffuse Cutaneous Disease
Corrie Poelman¹, Laura K. Hummers², Fredrick M. Wigley², Cynthia Anderson¹, Francesco Boin² and Ami A. Shah², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: A subset of patients with active diffuse cutaneous scleroderma has refractory disease despite traditional immunosuppressive therapy. In this retrospective observational study, we investigated whether…